Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
gene therapy genetically engineered cell |
| gptkbp:advantage |
off-the-shelf availability
|
| gptkbp:benefit |
rapid treatment availability
standardized product |
| gptkbp:challenge |
immune rejection
limited persistence in host |
| gptkbp:clinicalTrialPhase |
investigational
|
| gptkbp:derivedFrom |
donor T cells
|
| gptkbp:distinctFrom |
autologous CAR-T cells
|
| gptkbp:engineeredToExpress |
chimeric antigen receptor (CAR)
|
| https://www.w3.org/2000/01/rdf-schema#label |
allogeneic CAR-T cells
|
| gptkbp:modifiedToReduce |
T cell receptor (TCR) expression
|
| gptkbp:regulates |
not yet FDA approved (as of 2024)
|
| gptkbp:relatedTo |
gptkb:CRISPR/Cas9
gene editing universal CAR-T cells |
| gptkbp:riskFactor |
graft-versus-host disease (GVHD)
host-versus-graft rejection |
| gptkbp:studiedBy |
academic institutions
biotechnology companies |
| gptkbp:target |
tumor antigens
|
| gptkbp:usedFor |
gptkb:cancer
hematologic malignancies |
| gptkbp:bfsParent |
gptkb:Chimeric_Antigen_Receptor_T-cell_therapy
|
| gptkbp:bfsLayer |
8
|